Efficacy of different statins for primary prevention of atrial fibrillation in male and female patients: A nationwide population-based cohort study

International Journal of Cardiology

Volumn 168, Issue 4, 2013, Pages 4367-4369

  Hung, Chen Ying ^a   Hsieh, Yu Cheng ^a,b   Wang, Kuo Yang ^a,c   Huang, Jin Long ^a,b,c   Loh, El Wui ^d   Lin, Ching Heng ^a   Wu, Tsu Juey ^a,b,c  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^d Kaohsiung Municipal Kai Syuan Psychiatric Hospital   (Taiwan)

Author keywords

Atrial fibrillation; Gender; Statin; Upstream therapy

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGE DISTRIBUTION; AGED; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CEREBROVASCULAR ACCIDENT; CHRONIC LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG POTENCY; FEMALE; HEART ATRIUM FIBRILLATION; HEART DEATH; HUMAN; HYPERTENSION; INFLAMMATION; KIDNEY DISEASE; LETTER; LIPOPHILICITY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OXIDATIVE STRESS; POPULATION RESEARCH; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SEX DIFFERENCE; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; VASCULAR DISEASE; ATRIAL FIBRILLATION; MIDDLE AGED; TREATMENT OUTCOME;

ATRIAL FIBRILLATION; COHORT STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PRIMARY PREVENTION; TREATMENT OUTCOME;

EID: 84886246622     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.05.057     Document Type: Article

References (10)

1. C.Y. Hung, C.H. Lin, and W. Loh el CHADS(2) score, statin therapy, and risks of atrial fibrillation Am J Med 126 2013 133-40 e1
2. W.T. Fang, H.J. Li, and H. Zhang The role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials Br J Clin Pharmacol 74 2012 744 756
3. K.M. Dale, C.I. Coleman, and S.A. Shah Impact of gender on statin efficacy Curr Med Res Opin 23 2007 565 574
4. C.Y. Hung, C.H. Lin, and K.Y. Wang Dosage of statin, cardiovascular comorbidities, and risk of atrial fibrillation: a nationwide population-based cohort study Int J Cardiol 168 2 2013 1131 1136
5. J.M. Pena, J. MacFadyen, and R.J. Glynn High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial Eur Heart J 33 2012 531 537
6. C.W. Lee, S.J. Kang, and J.M. Ahn Comparison of effects of atorvastatin (20 mg) versus rosuvastatin (10 mg) therapy on mild coronary atherosclerotic plaques (from the ARTMAP trial) Am J Cardiol 109 2012 1700 1704
7. L. Sironi, E. Gianazza, and P. Gelosa Rosuvastatin, but not simvastatin, provides end-organ protection in stroke-prone rats by antiinflammatory effects Arterioscler Thromb Vasc Biol 25 2005 598 603
8. J. Li, Y.M. Sun, and L.F. Wang Comparison of effects of simvastatin versus atorvastatin on oxidative stress in patients with coronary heart disease Clin Cardiol 33 2010 222 227
9. S. Tonstad, E. Sandvik, and P.G. Larsen Gender differences in the prevalence and determinants of the metabolic syndrome in screened subjects at risk for coronary heart disease Metab Syndr Relat Disord 5 2007 174 182
10. M. Nakhjavani, A. Morteza, and A. Meysamie Serum heat shock protein 70 and oxidized LDL in patients with type 2 diabetes: does sex matter? Cell Stress Chaperones 16 2011 195 201